ABSTRACT
Introduction
Hemorrhagic shock is responsible for 30 to 40% of all injury related deaths, and is the most common cause of potentially preventable death from trauma. Approximately 50% of trauma deaths within the first 48 hours after injury are caused by uncontrolled bleeding and hemostatic dysfunction 1 . Thus, expeditious hemorrhage control is important to decrease mortality and prevent severe coagulopathy. Trauma associated coagulopathy is an early and primary event in hemorrhaging trauma victims. Approximately 25% of severely injured patients are coagulopathic at admission 2 . Studies have shown that the presence of coagulopathy is associated with a 4 fold increased mortality in trauma 2, 3 . Unraveling the mechanisms of trauma associated coagulopathy is a current topic of research.
Trauma associated coagulopathy has several key precursors, consequently it is difficult to determine the precise mechanism 2 . Hence, pre-emptive treatment of this condition has gained considerable support 4, 5 . The addition of procoagulant pharmacological agents to that treatment strategy has shown promising results 6, 7 . Because of the multifactorial nature of TAC, it is conceivable that pharmacological agents with distinct pro-coagulant effects may be employed synergistically to treat this condition .
Coagulation factor XIII is a protransglutaminase that was initially called fibrin stabilizing factor, and labeled factor XIII 20 years after its discovery 8, 9 . Even though, FXIII was originally described for its role on fibrin cross-linkage and clot stabilization, additional important hemostatic functions have been attributed to this protein [10] [11] [12] [13] . A purified concentrate of FXIII has been marketed in Europe for more than 20 years. Replacement therapy with that concentrate is a widely accepted treatment for acquired and congenital deficiency of FXIII, as well as, supportive therapy in cases of poor wound healing 8, 11, 14 . Similarly, desmopressin acetate
(1-deamino-8-d-arginine vasopressin; DDAVP) has been used in the management of patients with hemophilia A and von Willebrand disease for more than 30 years 15 . DDAVP increases plasma levels of both factor VIII (FVIII) and von Willebrand factor and enhances platelet adhesion to injured endothelium 15, 16 .
In the present study, we sought to investigate the acute hemostatic effect of FXIII and DDAVP in a model of uncontrolled hemorrhagic shock that incorporates fluid resuscitation strategies currently used.
Methods
The study was approved by the Animal Research Committee, 
Hemorrhage procedures
All animals were placed on a heating pad to maintain rectal temperature above 35 o C during the experiment as previously described 17 . In brief, MAP was continuously 
Statistical analysis
Thromboelastometry results were compared using the percentages of the differences between the baseline values of the medians. Whereby, differences between the baseline and the final value of each parameter were calculated. 
Results

Hemodynamic and metabolic response to hemorrhage
Intra-abdominal blood loss, scanning electron microscopy, and fluid infusion
Fluid resuscitation strategy aimed at restoring MAP to baseline levels (Group 6) resulted in significantly higher intraabdominal blood loss (22.3 ml/Kg ± 2.1; p<0.05) compared to permissive hypotension alone (Group 9; 11.5ml/Kg ± 2.5). Overall, the mean volume of LR infused in NBP resuscitated groups was 213ml/Kg ± 13.6 and only 81.5ml/Kg ± 6.6 in pH (p<0.05). 
Discussion
Damage control resuscitation in trauma encompasses strategies aimed at hemorrhage control, adequate systemic perfusion, and expeditious addressment of coagulopathy 4 .
The latter, ultimately consists of judicious use of crystalloids and high ratio of balanced blood products to PRBC 5 . More recently, early fibrinolysis, platelet dysfunction, clotting factor inactivation and depletion, were described in acute traumatic coagulopathy [18] [19] [20] . To approach those multiple conditions, pharmacological agents have been incorporated in the management of coagulopathy 6, 7 .
The main findings of this study were that FXIII and DDAVP used concomitantly with permissive hypotension resuscitation (group 5) significantly improved thromboelastometry parameters compared to normotensive fluid resuscitation strategy used alone (group 6). Moreover, the former strategy also resulted in less intra-abdominal bleeding. Interestingly, CT significantly improved with supplementary FXIII (group 2), and alpha angle improved with infusion of FXIII in conjunction with DDAVP (group 4), despite normotensive resuscitation in both groups. These findings suggest that detrimental effects of high volume infusion on initial coagulation parameters were partially abrogated by FXIII and DDAVP. These results are consistent with other reports, which showed that, even though FXIII is primarily responsible fibrin cross-liking and final clot stabilization, it also participates in earlier stages of coagulation 12, 13, 21, 22 .
We hypothesize that the improvement in early thromboelastometry parameters in our model could be attributed to the rapid activation of supplementary FXIII by thrombin;
whereby pro-transglutaminase plasma FXIII is converted into activated FXIII 21 . Additionally, DDAVP reduces the lag phase of thrombin generation by increasing FVIII, von Willebrand factor, and platelet organelle calcium (Ca 2+ ) 23 . Therefore, more thrombin is available to activate both FXIII and platelets, and to initiate fibrin polymerization from fibrinopeptide cleavage 24 . In accordance with those findings, our results showed that even in the absence of primed hemostasis, as in non-hemorrhaged animals, CT was This finding is consistent with previous research which showed that fibrinogen, and ultimately fibrin, lowers the concentration of thrombin required to activate FXIII 13 . In another study, improvement in thromboelastometric parameters of healthy volunteers, was only detected in blood samples that were incubated with FXIII and fibrinogen concomitantly 25 .
It is important to bear in mind that there are limitations to the effectiveness of FXIII on coagulation. Factor XIII activity should be increased to 20 to 30% to prevent surgical bleeding and poor wound healing, and an activity level of less than 50% adequately responds to treatment with FXIII concentrate 8, 11 .
However, supplementary infusion of FXIII once activity levels are above 50% does not necessarily improve thromboelastographic parameters 12, 13 . This could explain the unanticipated lack of improvement in MCF after supplementary FXIII infusion in our study 12, 13, 22, 26 . That was also noticed despite supplementary DDAVP infusion, and regardless of the fluid resuscitation strategy.
Even though, DDAVP activation of plasminogen activator (PA) could have played a role in abrogating an increase in MCF we do not believe that this was the case in the study herein 27 . 13, 25 .
In this study, fluid replacement was a major determinant of blood loss. Permissive hypotension clearly led to decreased bleeding compared to normotensive fluid resuscitation.
Mechanistically, the reduction in blood loss with permissive hypotension can be attributed to a combination of events. According to Laplace's law, permissive hypotension decreases vascular wall tension and delays peak pulse pressure. Consequently, more time is allowed before undesirable pressure is applied to an initially vulnerable clot 28 . Moreover, permissive hypotension contributes to vasoconstriction and reduces dilutional effect on coagulopathy 4, 19 .
Interestingly, our results failed to demonstrate additional decrease in intra-abdominal blood loss with supplementary infusion of FXIII and or DDAVP to pH compared to pH used alone. This finding is consistent with other research which showed that the major determinant of early hemorrhage and rebleeding from clot dislodgment, in uncontrolled hemorrhagic shock models, is the mechanical effect of increased blood pressure, not coagulopathy 29 .
This study has several limitations. Even though, our model simulates some conditions encountered in traumatic hemorrhage, rabbits have different hemodynamic and hemostatic responses compared to humans 30 .
Severe hypothermia and blood product transfusion were not included in this model, decreasing clinical relevance.
Furthermore, only the acute phase of resuscitation from hemorrhage was assessed. Understanding the late effects of the resuscitation strategies used herein require further research. Lastly, lack of assessment of clotting factors, fibrinolysis, and platelet activity precluded a more comprehensive mechanistic analysis of our results.
Conclusions
Normotensive resuscitation provokes more bleeding and worsens coagulation compared to pH, that is partially reversed by factor XIII and desmopressin. FXIII and DDAVP can synergistically improve coagulation. Permissive hypotension reduces bleeding regardless of those agents.
